Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when KLRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsKailera Therapeutics reports Q1 2026 financial results
Filed May 26, 2026 · Period ending May 26, 2026 · ~1 min read
Key Changes
-
high
Company issued press release disclosing financial results for quarter ended March 31, 2026. Specific figures and guidance are in the attached exhibit, not the 8-K body itself.
Item 2.02 verify on EDGAR →
Summary
Kailera Therapeutics filed an 8-K to announce its first quarter 2026 financial results through a press release dated May 26, 2026. This is a routine quarterly earnings disclosure required for public companies. The actual financial figures, operational updates, and any forward guidance are contained in the press release furnished as Exhibit 99.1, which is not included in the main 8-K text.
Investors should review the full press release exhibit to understand the company's Q1 performance, cash position, and any commentary on clinical trial progress or business development. Watch for any subsequent analyst calls or investor presentations that may provide additional context on the quarter's results and management's outlook for the remainder of 2026.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 26, 2026, Kailera Therapeutics, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended March 31, 2026.
The company disclosed its financial results for the first quarter of 2026 ending March 31, 2026. The actual financial figures are contained in the press release furnished as Exhibit 99.1, which is not included in this 8-K body. This is a routine quarterly earnings announcement.
Event · Item 9.01 — Financial Statements and Exhibits
Kailera Therapeutics filed an 8-K attaching an earnings press release dated May 26, 2026.
Added in current filing · verify on EDGAR →
99.1 Earnings Press Release dated May 26, 2026.
The company disclosed financial results through an earnings press release dated May 26, 2026. The actual content of the press release is not included in this 8-K body, only referenced as Exhibit 99.1. Investors should review the full exhibit to understand the financial performance and any guidance provided.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 28, 2026 · How we verify